Research on individualisation of tacrolimus regimen based on the CYP3A5, MDR1 and PXR genotype-guided combination therapy (coadministration with diltiazem or Schisandra sphenanthera extract): a randomised controlled trial.

Trial Profile

Research on individualisation of tacrolimus regimen based on the CYP3A5, MDR1 and PXR genotype-guided combination therapy (coadministration with diltiazem or Schisandra sphenanthera extract): a randomised controlled trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2013

At a glance

  • Drugs Tacrolimus (Primary) ; Diltiazem
  • Indications Renal transplant rejection
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 04 Jan 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 29 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top